Theriva Biologics TOVX
NYSE TOVX
$0.19 0.00 (-1.83%)
As of: Oct 22, 2026 · 10:38 AM EDT

Theriva Biologics (TOVX) Research & Development (2010 - 2026)

Updated

Theriva Biologics (TOVX) posted Research & Development of $1.27 million for Q2 2026, down 35.1% from $1.95 million a year earlier but up 257.2% from the prior quarter.

Analysis

Theriva Biologics (TOVX) Research & Development (2010 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Research & Development at Theriva Biologics was $5.31 million, down 49.7% year-over-year; for FY2025, it came in at $8.6 million, down 28.5% from FY2024.

  • Annual Research & Development shows a five-year compound annual growth rate of 10.9% (FY2020 to FY2025).
  • In prior years, Theriva Biologics' Research & Development was $12.03 million in FY2024 (-15.9%), $14.31 million in FY2023 (+22.1%), $11.72 million in FY2022 (+50.3%) and $7.8 million in FY2021 (+52.0%).
  • Quarterly Research & Development has run from a low of $355,000 in Q1 2026 to a high of $4.2 million in Q4 2023 over five years.
  • On a year-over-year basis, Research & Development has declined in each of the last nine quarters, with an average decline of 37.7% over the last eight quarters.
  • The strongest year-over-year quarter for Research & Development in the past five years was Q4 2021, with growth of 183.9%; the weakest was Q1 2026, with a decline of 88.0%.
  • According to Business Quant data, Research & Development for the three prior quarters was $355,000 (Q1 2026), $1.13 million (Q4 2025) and $2.55 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Eli Lilly 1,166.12 Bn 1,134.70 Bn 19.71 Bn 3.82 Bn
2 Johnson & Johnson 634.67 Bn 553.20 Bn 17.26 Bn 3.65 Bn
3 AbbVie 503.03 Bn 476.14 Bn 12.70 Bn 2.34 Bn
4 Merck 377.66 Bn 332.04 Bn 12.21 Bn 9.74 Bn
5 Novartis Ag 303.82 Bn 267.81 Bn 11.24 Bn 2.85 Bn
6 Astrazeneca 266.80 Bn 240.49 Bn 12.86 Bn 4.05 Bn
7 Amgen 240.87 Bn 196.27 Bn 7.24 Bn 1.87 Bn
8 Gilead Sciences 193.45 Bn 167.65 Bn 6.22 Bn 1.76 Bn
9 Pfizer 172.20 Bn 118.84 Bn 10.94 Bn 2.81 Bn
10 Theriva Biologics 8.86 Mn -37.49 Mn - 1.27 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.27 Mn
Mar 31, 2026 355,000.00
Dec 31, 2025 1.13 Mn
Sep 30, 2025 2.55 Mn
Jun 30, 2025 1.95 Mn
Mar 31, 2025 2.97 Mn
Dec 31, 2024 2.89 Mn
Sep 30, 2024 2.73 Mn
Jun 30, 2024 2.95 Mn
Mar 31, 2024 3.46 Mn
Dec 31, 2023 4.20 Mn
Sep 30, 2023 4.01 Mn
Jun 30, 2023 3.13 Mn
Mar 31, 2023 2.98 Mn
Dec 31, 2022 3.07 Mn
Sep 30, 2022 2.57 Mn
Jun 30, 2022 3.49 Mn
Mar 31, 2022 2.60 Mn
Dec 31, 2021 2.78 Mn
Sep 30, 2021 1.97 Mn
API Access

Theriva Biologics Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=TOVX&period=max&api_key=YOUR_API_KEY